(NASDAQ: HOWL) Werewolf Therapeutics's forecast annual revenue growth rate of 29.76% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Werewolf Therapeutics's revenue in 2024 is $19,943,000.On average, 2 Wall Street analysts forecast HOWL's revenue for 2024 to be $1,004,323,989, with the lowest HOWL revenue forecast at $854,743,820, and the highest HOWL revenue forecast at $1,153,904,157. On average, 2 Wall Street analysts forecast HOWL's revenue for 2025 to be $1,089,798,371, with the lowest HOWL revenue forecast at $42,737,191, and the highest HOWL revenue forecast at $2,136,859,550.
In 2026, HOWL is forecast to generate $2,136,859,550 in revenue, with the lowest revenue forecast at $2,136,859,550 and the highest revenue forecast at $2,136,859,550.